Medical Device Contract Manufacturing Market

Jabil, Inc. (US) and Flex, Ltd. (Singapore) are Leading Players in the Medical Device Contract Manufacturing Market

The global medical device contract manufacturing market is estimated to reach USD 113.3 billion in 2026 from USD 65.9 billion in 2021, at a CAGR of 11.5% during the forecast period. The key factors driving the growth of the medical device contract manufacturing market include the overall growth of the medical devices market, mainly due to rising disease prevalence, life expectancy, and the geriatric population. Technological advancement has prompted end users to overhaul or update their manufacturing systems. As this is a costly process, they look to contract manufacturing. In addition to this, the COVID-19 outbreak has accelerated the adoption of advanced diagnostics and patient care devices for better treatment management. However, market growth is impeded by the growing consolidation in the medical devices market. Larger players, to develop their manufacturing capabilities to save costs, focus on the acquisition of smaller players and CMOs themselves. This may affect the overall pace of market growth.

The prominent players in the medical device contract manufacturing industry are Flex, Ltd. (Singapore), Jabil, Inc. (US), TE Connectivity, Ltd. (Switzerland), Sanmina Corporation (US), Nipro Corporation (Japan), Celestica International (Canada), Plexus Corporation (US), Benchmark Electronics, Inc. (US), Integer Holdings Corporation (US), Gerresheimer Ag (Germany), West Pharmaceutical Services, Inc. (US), Nortech Systems, Inc. (US), Consort Medical PLC (UK), Kimball Electronics Inc. (US), and Teleflex Incorporated (US), Nordson Corporation (US), Tecomet, Inc. (US), SMC Ltd. (US), Nemera (France), and Tessy Plastics Corporation (US), among others. These players have adopted various growth strategies such as acquisition, product launches, and expansion to increase their presence and reach in the medical device contract manufacturing market.

To know about the assumptions considered for the study download the pdf brochure

Jabil, Inc.: The company is a leading player in the market. The company offers a focused range of products and services in the healthcare domain as well as advanced manufacturing technologies. This factor, coupled with its robust presence of manufacturing facilities worldwide, further adds to its value. The company also serves some of the top companies in other domains, which strengthens its brand recognition. Jabil also focuses on collaborating with major pharma and medical device companies for contract manufacturing. In February 2020, it launched Jabil Healthcare in collaboration with Nypro to deliver advanced manufacturing solutions. Later in the same year, it launched substantial face mask manufacturing operations in the US to address the demand for face masks and other personal protective equipment (PPE) amid the coronavirus pandemic. Through its R&D efforts, the company offers its customers highly automated, continuous flow manufacturing process technologies for precise and aesthetic mechanical components and system assembly. It invested USD 38.5 million, USD 42.9 million, and USD 44.1 million in 2018, 2019, and 2020, respectively for research and development.

COVID-19 Impact: The COVID-19 global pandemic adversely affected the company’s employees, operations, supply chain, and distribution system. This resulted in increased expenses, primarily related to additional labor costs and the procurement of personal protection equipment for employees globally and caused a reduction in factory utilization due to travel disruptions and restrictions. Additionally, some of the company’s suppliers were similarly impacted by the COVID-19 pandemic, leading to supply chain constraints, including difficulties in sourcing materials necessary to fulfil customer production requirements and challenges in transporting completed products to end customers.

The company’s gross profit as a percentage of its net revenue decreased for the fiscal year ended August 31, 2020, compared to the fiscal year ended August 31, 2019, primarily due to an increase of USD 108.8 million in incremental and idle labor costs associated with travel disruptions and governmental restrictions, largely related to the COVID-19 outbreak.

Flex Ltd.: The company provides design, engineering, manufacturing, and supply chain services and solutions to original equipment manufacturers worldwide. The company is contracted by some of the major players in the electronics industry. Its expertise in the electronics segment has given the firm an advantage in the medical devices segment. The company has vast operations globally, with 40 manufacturing sites located across the globe. Although the medical devices segment is not its core business, expertise from the electronics market will surely help the company develop innovative products and solutions in the future.

The company focuses on agreements and partnerships to strengthen its service portfolio in the medical devices and other healthcare segments. In October 2018, Flex partnered with Novo Nordisk (Denmark) to develop digital health solutions for diabetes patients. Flex continues to make substantial investments in resources such as research & development, technology licensing, test and tooling equipment, facility expansions, and personnel requirements to create world-class components. Each year, it invests a considerable share of its revenue in the research & development of products to maintain its position in the market.

COVID-19 Impact: The spread of COVID-19 across the globe has resulted in the implementation of several infection control measures, including travel bans and restrictions, quarantines, shelter-in-place orders, and shutdowns. These measures materially impacted the workforce and operations of the company, resulting in disruptions at manufacturing facilities. Flex also experienced reduced capacity utilization levels, supply chain disruptions, and temporary shortages of skilled employees. This caused an increase in the operational expenses and other costs related to requirements implemented to mitigate the impact of the pandemic. Additionally, it caused delays and limitations on the ability of the customers to make timely payments. Flex also faced workforce shortages due to illnesses, quarantines, governmental actions, and other restrictions. The net sales for the fiscal year 2020 decreased by 8% (or USD 2 billion) to USD 24.2 billion from the previous year because of COVID-19.

Sanmina Corporation: The company has established itself as a global player with a strong presence in almost 40 countries worldwide. The company focuses on technological advancements by offering diverse electronic medical devices as well as custom medical devices. The company follows changing trends like Industry 4.0 by focusing on automation and cloud-based functioning in its operations. Sanmina also caters to a host of other market segments apart from medical device manufacturing. The company’s R&D expenses were USD 22.6 million, USD 27.6 million, and USD 30.8 million in 2020, 2019, and 2018, respectively. As a percentage of its net sales, the company’s R&D expenses were 0.3%, 0.3%, and 0.4% in 2020, 2019, and 2018, respectively.

COVID-19 Impact: At the start of the second quarter of 2020, the company’s sales were negatively impacted by the COVID-19 global pandemic, which resulted in supply shortages, restrictions on the types of products it could manufacture, and disruptions to the company’s operations and those of its customers.

The COVID-19 pandemic has had, and will likely continue to have, a significant impact on the company’s operations and financial condition by reducing the demand from its customers, by interrupting the flow of components needed for its customers’ products, and by limiting the operations or productivity of its manufacturing facilities. Interruptions in the supply of components and the reduced capacity of logistics providers caused by the COVID-19 global pandemic have resulted in increased component prices and delays in product shipments to customers, both of which would decrease the company’s revenue and margins, as well as increase its inventory of other components, which would reduce the operating cash flow.

Related Reports:

Medical Device Contract Manufacturing Market by Device Type (IVD (Equipment, Consumable), Cardiovascular, Diabetes Care, Drug Delivery, Orthopedic, Ophthalmic, Endoscopy Devices), Class of Device (Class I, II, III), & Services - Global Forecast to 2026

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

Report Code
MD 7111
RI Published ON
7/14/2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Medical Device Contract Manufacturing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved